The Malaysia-Thailand Medical Device Regulatory Reliance Pilot 2026 is a 3-month program running from 1 February to 30 April 2026, designed to streamline registration of class B/C/D (2/3/4) medical devices. By leveraging mutual regulatory assessments, the pilot reduces duplicated reviews, shortens time-to-market, lowers costs, and gives patients faster access to safe and high-quality devices. Manufacturers with prior approval in either country can take advantage of this fast-track regulatory pathway.
Strategic Importance of the Pilot
- Marks a new chapter in regulatory convergence and industry cooperation between Malaysia and Thailand.
- Serves as a sandbox for ASEAN member states in regulatory reliance.
- Reduces duplication of regulatory assessments and accelerates device availability.
Benefits of the Malaysia-Thailand Regulatory Reliance Program
- Faster approvals: Both countries rely on each other’s regulatory assessments.
- Cost efficiency: Minimizes duplicated reviews and associated fees.
- Improved patient access: Innovative and high-quality devices reach the market sooner.
Malaysia Registration Pathway
- Eligible Devices: Class 2/3/4 medical devices registered with Thai FDA.
- Review Route: Verification route (abridged pathway) via Conformity Assessment Body (CAB).
- Timeline: Review in 30 working days (compared with 60 days under full route) and device registration completed within 30 working days.
- Benefits: Reduces regulatory burden and accelerates market entry.
Learn more about MDA Malaysia Medical Device Registration
Thailand Registration Pathway
- Eligible Devices: Class B/C/D devices registered with MDA Malaysia.
- Review Route: Full submission pathway without external expert review.
- Timeline: Reduced from 150 to 120 calendar days; expert review fees waived.
- Benefits: Streamlines approvals and reduces costs for manufacturers.
Learn more about Thai FDA Medical Device Registration
Who Benefits Most
- Devices without reference country approval (USA, EU, Canada, Australia, Japan) gain significant advantages under this pilot.
- Devices already approved in reference countries do not gain additional benefits under this Reliance pathway.
- Products with reference country approval older than 1 year already qualify for Thailand’s expedited pathway.
Future Reliance Programs
- At the Malaysia Pharma and Healthcare Expo 2025, MDA indicated plans to explore reliance with India, Brazil, Indonesia, Pakistan, Egypt, UAE, and Turkey.
- Thailand is the first confirmed pilot, but more Reliance programs may be announced later in 2026.
Duration and Limitations
- Similarly, there is no guarantee that the Malaysia-Thailand Reliance Pilot will continue after 30 April 2026.
- Manufacturers with non-reference country approved devices should take advantage while the pilot is active.
Key Takeaways for Manufacturers
- Streamlined approval pathways can significantly shorten time-to-market.
- Cost and regulatory burden are reduced.
- Early adoption is crucial due to the limited pilot duration.
- Supports regional harmonization and sets a precedent for future ASEAN regulatory reliance initiatives.
External Links:
